REG - Immupharma PLC - Collaboration with Orano on ImmuPharma Peptide

ImmuPharmaAnnouncement

06/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230306:nRSF9226Ra&default-theme=true

RNS Number : 9226R  Immupharma PLC  06 March 2023

 
6th March 2023

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Collaboration with Orano on ImmuPharma's peptide technology as a vector for
cancer radiotherapy

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, is delighted to announce that it has signed an initial collaboration
agreement on the Company's peptide technology, with Orano SA ("Orano"), a
leading international corporation and a key player in the nuclear energy
sector.

 

Key points:

 

·    Orano has paid a small undisclosed amount to ImmuPharma for a
12-month collaboration to identify suitable radiotherapy candidates for the
treatment of cancer.

·    ImmuPharma has agreed to provide its peptide technology, to explore
the potential to allow delivery of a potent radioactive isotope to the core of
a cancer cell.

·    Our team based in Bordeaux, (ImmuPharma Biotech), in conjunction with
Orano and the Cancer Research Centre of Lyon (CRCL), will work together to
identify molecules that can carry the radioactive entity.

·    Any potential new cancer therapeutic using ImmuPharma's peptide
technology, discovered as part of the collaboration will be subject to a full
licensing agreement between ImmuPharma and Orano in preparation for further
development by Orano.

·    The therapeutic goal is to use ImmuPharma's peptide technology to
deliver a radioactive bullet to the nucleus of cancer cells, killing the cell
with minimal impact on surrounding tissue.

·    The radiopharmaceuticals market is expected to achieve global sales
*€8.5bn by 2031. The combination of ImmuPharma's peptide technology and a
powerful radioactive bullet is an exciting new approach with significant
commercial potential.

 

Further details of this development program will be communicated over the next
12 months.

 

*Source: Transparency Market Research, November 2022.

 

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:

 

"We are delighted to have signed this agreement with Orano. It is the ideal
program for our peptide asset given its ability to enter the nucleus of cancer
cells. The combination of our peptide as a nuclear targeting vector, combined
with the short-range destructive qualities of Orano's radioactive bullet makes
this a logical collaboration for both companies. Furthermore, we potentially
create a new product life cycle for our peptide. We look forward to working
with Orano and the Cancer Research Centre of Lyon over the next 12 months."

 

 

 

 

Commenting on the announcement, Guillaume Dureau, Orano's Director of Research
& Development and Innovation said:

"For Orano, it is a real opportunity to evaluate the potential of a highly
promising compound, combining one of our new radioisotopes with a promising
peptide previously developed by Immupharma. This will enable us to expand and
strengthen our pipeline of innovative radiopharmaceuticals."

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

*Ends*

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

About Orano

As a recognized international operator in the field of nuclear materials,
Orano delivers solutions to address present and future global energy and
health challenges. Its expertise and mastery of cutting-edge technologies
enable Orano to offer its customers high value-added products and services
throughout the entire fuel cycle. Every day, the Orano group's 17,000
employees draw on their skills, unwavering dedication to safety and constant
quest for innovation, with the commitment to develop know-how in the
transformation and control of nuclear materials, for the climate and for a
healthy and resource-efficient world, now and tomorrow.

 

Orano, giving nuclear energy its full value. Orano looks continuously at
opportunities to value material derived from its core nuclear energy
activities in a sustainable approach. Nuclear medicine therapy is one of the
currently explored strand realized with the production of lead-212 (a rare
radioisotope used for targeted alpha therapy) and clinical studies underway.
Orano aims to further strengthen its development in the medical field and
complete its pipeline with new promising radioisotopes.

 

Further information can be found at: www.orano.group (http://www.orano.group)

 

 

About Cancer Research Center of Lyon

The Cancer Research Centre of Lyon (CRCL, UMR Inserm 1052 - CNRS 5286 - Centre
Léon Bérard) is a research structure affiliated with the University Claude
Bernard Lyon 1, the national health and research bodies (Inserm and CNRS), the
Léon Bérard Comprehensive Cancer Centre (CLB) and with the Lyon University
Hospitals (HCL) as clinical partners. The CRCL was officially created in
January 2011 and its contract was recently renewed for the 2020-2026 period.
It comprises 24 teams, totalling about 600 members, including 150 researchers
and lecturers. The CRCL aims at increasing its international visibility and
the attractiveness of the Lyon cancer research cluster, at facilitating the
transfer of knowledge from fundamental cancer research to clinical
applications in oncology, and at developing teaching and training in oncology.

 

Further information can be found at: www.crcl.fr (http://www.crcl.fr)

 

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRJIMTTMTBMBAJ